Profitable Telemedicine Company Investment Opportunity in Sydney, Australia
Equity investment opportunity: Telehealth company providing cutting-edge technology for digital care.
This transaction has concluded.
Premium Plan
| Established | 5-10 year(s) |
| Employees | 10 - 50 |
| Legal Entity | Private Limited Company |
| Reported Sales | USD 108 thousand |
| Run Rate Sales | USD 157 thousand |
| EBITDA Margin | 27 % |
| Industries | Telemedicine |
| Locations | Sydney + 1 more |
| Local Time | 9:00 PM Asia / Kuala Lumpur |
| Listed By | Advisor / Business Broker |
| Status | Active |
Partial Stake Sale
USD
1.63 million
for
20.0%
stake
(Native Currency: AUD 2,500,000)
Reason: - The company is a part of the global telehealth market that is growing exponentially, the telehealt...
View More
Interested to connect with advisors
Documents
Pitch Deck
(12.5 MB)
Sapphire Scan
(37.0 KB)
Products and Services
(301.3 KB)
The Ukranian Crisis
(91.8 KB)
About the Services
(177.2 KB)
Partners
(97.9 KB)
Business Overview
The company addresses a global telehealth market size that is expected to reach US9.35 billion by the end of this year with an impressive 32.5 % annual growth rate. The company is an active service provider in the Ukrainian crisis displaying exceptional healthcare services.
Business is registered in Australia with a branch in Singapore but employees work remotely.
Business is listed by an advisory company based in Malaysia.
Key Metrics:
- AUD 1.7 million platform turnover.
- 18k+ consultation sessions.
- Zero debt and zero downtime.
- Valuation = AUD 10 million.
- Targeted purchase back premium = 25%
- Multiple media coverage and success case studies.
- Strong committed management team of advisors and board directors.
- Dividend payout of 20% per year from net profit.
Business is registered in Australia with a branch in Singapore but employees work remotely.
Business is listed by an advisory company based in Malaysia.
Key Metrics:
- AUD 1.7 million platform turnover.
- 18k+ consultation sessions.
- Zero debt and zero downtime.
- Valuation = AUD 10 million.
- Targeted purchase back premium = 25%
- Multiple media coverage and success case studies.
- Strong committed management team of advisors and board directors.
- Dividend payout of 20% per year from net profit.
Products & Services Overview
- Remote medical consultation.- Online prescription stream.
- Corporate wellness package.
- Telehealth tech for allied health providers.
- Telehealth for managed care operators.
- Virtual healthcare for the crisis.
Assets Overview
- Cloud technologies.- Virtual service platform.
- Strong network of affiliates and partners including AWS, Wolters Kluwer, Ndis, etc.
Facilities Overview
- The company is a tech-based solution provider in a remote environment.- Employees work remotely and there is no office.
Capitalization Overview
- The business is currently funded by MVP and Angel investors.- Zero debt.
- Total number of shareholders: 20.
- Propotion of shares: Founder 50% and others 50%
Recent Activity
-
Earlier than 15 daysFinance Director, Finance - IT, Adelaide, Individual Investor / Buyer connected with the Business
-
Earlier than 15 daysDirector, Healthcare - Pharma, Dubai, Individual Investor / Buyer connected with the Business
-
Earlier than 15 daysCEO, Biotechnology Research, Singapore, Individual Investor / Buyer connected with the Business
Tags:
Profitable Telemedicine Company Investment Opportunity in Sydney, Australia
·Profitable Telemedicine Company Investment Opportunity in Singapore
·Invest in Profitable Telemedicine Company in Sydney, Australia
·Profitable Telemedicine Company Investment Opportunity
·Invest in Profitable Telemedicine Company in Singapore
·Investment Opportunity in Sydney, Australia
·Invest in Profitable Telemedicine Company
·Investment Opportunity in Singapore
·Invest in Sydney, Australia
·Invest in Singapore
Disclaimer: SMERGERS is a regulated marketplace for connecting business sell sides with investors, buyers, lenders and advisors. Neither SMERGERS represents nor guarantees that the information mentioned above is complete or correct. Note that SMERGERS is not liable for any loss, damage, costs, claims and expenses whatsoever arising from transacting with any other user from the website. The final responsibility of conducting a thorough due diligence and taking the transaction forward lies with the users. Please read best practices on SMERGERS.
